Circulating Endothelial Progenitor Cells in Type 1 Diabetic Patients: Relation with Patients&apos; Age and Disease Duration. by Arcangeli, A et al.
October 2017 | Volume 8 | Article 2781
Original research
published: 23 October 2017
doi: 10.3389/fendo.2017.00278
Frontiers in Endocrinology | www.frontiersin.org
Edited by: 
Gaetano Santulli, 
Columbia University, 
United States
Reviewed by: 
Celestino Sardu, 
Università degli Studi della Campania 
‘L. Vanvitelli’, Italy; Leiden University 
Medical Center, 
Netherlands  
Jessica Gambardella, 
University of Salerno, 
Italy
*Correspondence:
Annarosa Arcangeli  
annarosa.arcangeli@unifi.it
†Deceased
Specialty section: 
This article was submitted 
to Diabetes, 
a section of the journal 
Frontiers in Endocrinology
Received: 24 July 2017
Accepted: 04 October 2017
Published: 23 October 2017
Citation: 
Arcangeli A, Lastraioli E, Piccini B, 
D’Amico M, Lenzi L, Pillozzi S, 
Calabrese M, Toni S and Arcangeli A 
(2017) Circulating Endothelial 
Progenitor Cells in Type 1 Diabetic 
Patients: Relation with Patients’ 
Age and Disease Duration. 
Front. Endocrinol. 8:278. 
doi: 10.3389/fendo.2017.00278
circulating endothelial Progenitor 
cells in Type 1 Diabetic Patients: 
relation with Patients’ age and 
Disease Duration
Adolfo Arcangeli1†, Elena Lastraioli 2, Barbara Piccini3, Massimo D’Amico4, Lorenzo Lenzi3, 
Serena Pillozzi2, Maria Calabrese1, Sonia Toni4 and Annarosa Arcangeli 2*
1 Diabetology Unit, Prato Hospital, Prato, Italy, 2 Department of Experimental and Clinical Medicine, University of Florence, Florence, 
Italy, 3 Diabetology Unit, Azienda Ospedaliero Universitaria Meyer, Florence, Italy, 4 DI.V.A.L Toscana Srl, Sesto Fiorentino, Italy
Objectives: Circulating endothelial progenitor cells (cEPCs) have been reported to be 
dysfunctional in diabetes mellitus (DM) patients, accounting for the vascular damage and 
the ensuing high risk for cardiovascular disease (CVD) characteristic of this disease. The 
aim of the present study was to evaluate the number of circulating cEPCs in type 1 DM 
(T1DM) patients, without clinical vascular damage, of different ages and with different 
disease duration.
Methods: An observational, clinical-based prospective study was performed on T1DM 
patients enrolled in two clinical centers. cEPCs were determined by flow cytometry, 
determining the number of CD34/CD133/VEGFR2-positive cells within peripheral blood 
mononuclear cells (PBMCs).
results: The number of cEPCs was lower in adult T1DM patients, whilst higher 
in childhood/young patients, compared to controls of the same age range. When 
patients were grouped into two age groups (≥ or <20  years) (and categorized on 
the basis of the duration of the disease), the number of cEPCs in young (<20 years) 
patients was higher compared with older subjects, regardless of disease duration. 
A subset of patients with very high cEPCs was identified in the <20 years group.
conclusion: There is an association between the number of cEPCs and patients’ age: 
childhood/young T1DM patients have significantly higher levels of cEPCs, respect to 
adult T1DM patients. Such difference is maintained also when the disease lasts for 
more than 10 years. The very high levels of cEPCs, identified in a subset of childhood/
young patients, might protect vessels against endothelial dysfunction and damage. 
Such protection would be less operative in older subjects, endowed with lower cEPC 
numbers, in which complications are known to develop more easily.
Keywords: type 1 diabetes mellitus, endothelial progenitor cells, flow cytometry, diabetes duration, patients’ age
inTrODUcTiOn
Diabetes mellitus (DM) is characterized by long-term vascular damage to small vessels and 
major arteries and by an impaired vascular repair, which collectively leads to a higher risk of 
cardiovascular disease (CVD) (1). Contributory factors to the vascular impairment in DM include 
increased glucose level, other traditional cardiovascular risk factors, arterial wall inflammation, 
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and endothelial dysfunction (2). Endothelial dysfunction is 
considered the pivotal mechanism sustaining vascular injury, 
and hence the heightened cardiovascular burden in DM (3).
After a vascular injury, endothelial repair depends both 
on the migration and proliferation of endothelial cells of the 
vascular wall and by the arrival of endothelial progenitor cells 
(EPCs) from the bone marrow in the site of damage (4, 5). 
The release of EPCs from the bone marrow depends on the 
stimulatory effect of different growth factors/cytokines, such as 
VEGF and IL-8 (6, 7). In this light, a novel paradigm of CVD 
pathogenesis is the loss of normal endothelial turnover caused 
by a reduction of EPCs [reviewed by Shantsila et al. (8)].
A reduction of circulating EPCs (cEPCs) has been hypoth-
esized to promote the development and/or progression of vas-
cular dysfunction and CVD in DM (9). EPC dysfunction would 
also represent the molecular transducer in the mechanism 
through which risk factors negatively affect cardiovascular 
function in DM (10). Consistently, several reports have shown 
that both the number and functionality of cEPCs are reduced in 
type 2 DM (T2DM) and that such impairment is related to the 
morphological and functional alterations detected in periph-
eral vessels (9, 11–13). Furthermore, T2DM patients show 
low serum levels of those growth factors/cytokines known to 
trigger EPC release from the bone marrow, accounting for a 
reduced bone marrow stimulation and hence EPCs release 
(14). The levels of cEPCs and arterial wall stiffness in T2DM 
subjects are strictly correlated with glycemic control (15, 16). 
Interestingly, a clear correlation between EPC activity, glyce-
mic control, and myocardial savage has been recently demon-
strated (17). Hyperglycemia may per se affect EPC number and 
functional capacity, because it enhances EPC senescence and 
triggers apoptosis (18). Sirtuins have been identified as 
molecular mediators of the deleterious effect of hyperglycemia 
in EPCs (16, 19).
The scenario is apparently similar in Type 1 DM (T1DM), 
where a general reduction of cEPC number has been reported 
(20–24). Only Głowińska-Olszewska et al. (25) showed that con-
trary to adult population with diabetes, T1DM diabetic children 
have an increased number of EPCs.
Based on the latter data and on the clinical observation of 
less incidence of late vascular complications in T1DM when the 
onset of the disease is in childhood respect to adult age (26), 
we undertook a study aimed at determining the number of 
cEPCs in T1DM patients without clinical vascular damage, of 
different ages and disease duration.
MaTerials anD MeThODs
study Population
We performed an observational, clinical-based prospective 
study on type 1 diabetic patients treated at two different Italian 
centers: the Diabetic Unit of the Meyer Hospital in Florence 
and the Diabetic Unit of the Prato Hospital, Prato. The Meyer 
Hospital specifically enrolled childhood (age <10  years) and 
young (age 10–24  years) T1DM patients and age-matched 
controls; the Diabetic Unit of the Prato Hospital enrolled adult 
(25–59 years) T1DM patients and age-matched controls. Patients 
were enrolled after informed written consent in accordance with 
the Declaration of Helsinki. The study was approved by Local 
Ethical Committee. The enrollment started in January 2010 and 
ended on May 2012; patients were followed up until December 
2014. Inclusion criteria were the clinical diagnosis of T1DM 
from at least two years and the lack of clinical CV complica-
tions. In particular, patients were screened for hypertension, 
coronary artery disease, peripheral arterial disease, peripheral 
neuropathy, retinopathy, and nephropathy.
Twenty-two healthy individuals, selected within the same age 
range as T1DM patients, were enrolled as controls. None of the 
controls had a clinical history of diabetes. They had normal fast-
ing blood glucose levels and normal physical examination and 
had not received any medication.
sample Preparation
Mononuclear cells from peripheral blood mononuclear cell 
(PBMC) samples were isolated by density gradient centrifuga-
tion using Lympholyte (Cedarlane Laboratories, Burlington, 
ON, Canada). Briefly, 5  ml of peripheral blood were diluted 
1:2 with PBS and the diluted blood was stratified onto 5 ml of 
Lympholyte. Samples were centrifuged 30  min at room tem-
perature at 3,000  rpm without brake. After separation, white 
blood cells were recollected, diluted with PBS and centrifuged at 
1,200 rpm for 5 min at room temperature. Subsequently, pellet 
was treated with Red Cell Lysis Buffer, to ensure red blood cell 
removal and washed in PBS.
Fluorescence-activated cell sorting 
(Facs) analysis
The number of cEPCs was assessed by flow cytometry by deter-
mining the number of CD34/CD133/VEGFR2-positive cells. 
In particular, 100 µl of each sample prepared as described in the 
previous section, were stained with 1 µl each of FITC-CD34 (BD 
Biosciences, Franklin Lakes, NJ, USA), APC-CD133/2 (Miltenyi 
Biotec, Bergisch Gladbach, Germany), and PE-VEGFR-2 
(R&D Systems, Minneapolis, MN, USA), and incubated in the 
dark in ice for 15 min. For each sample, a control tube with no 
antibodies was prepared together with the stained tube. After 
washing the cells with PBS, FACS analysis was performed on 
a FacsCanto (BD Biosciences, Franklin Lakes, NJ, USA). The 
acquisition goal was 2 ×  105 events. Samples were analyzed 
gating a population with morphological characteristics bet-
ween lymphocytes and monocytes, evaluated on the basis of 
side scatter and forward scatter parameters. As evident from 
Figure 1, where representative dot-plots relative to a control 
and a T1DM patient (belonging to the “<20 y T1DM cohort”) 
are shown, the cEPC count is reported in Q2, that is a part of 
the P4 quadrant. Throughout the manuscript, “cEPC counts” 
refers to the absolute cEPC number per 2 × 105 PBMC.
statistical analysis
Data are given as mean ±  SEM. First of all, normality of the 
distribution of cEPC counts was assessed by Kolmogorov–
Smirnov test. In order to apply the correct type of T test (for 
FigUre 1 | Representative dot-plots of a control subject [left panel, circulating endothelial progenitor cells (cEPCs) = 8.7] and diabetic patient belonging to the 
“<20 y T1DM” cohort (right panel, cEPCs = 10.1). The cEPC count was performed as described in the Section “Materials and Methods” and gating a population 
with morphological characteristics between lymphocytes and monocytes (evaluated through side scatter and forward scatter). In the final plots, the cEPC count of 
each sample is reported in Q2 that is a part of P4 quadrant. “cEPC counts” refers to the absolute cEPC number per 2 × 105.
FigUre 2 | Flow diagram showing the rationale of the study. The end point of the first step of the study was the evaluation of the number of circulating endothelial 
progenitor cells (cEPCs) in adult and childhood/young patients, compared to age-matched controls. In the second step of the study, the end point was the 
association of the number of cEPCs with disease duration and/or patients’ age.
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Table 1 | Clinical characteristics of adult type 1 diabetes mellitus (T1DM) patients and control subjects enrolled for the setting up of circulating endothelial progenitor 
cell (cEPC) detection and evaluation.
Patient iD gender T1DM duration 
(years)
cePc age hba1c (%) bMi body  
weight (kg)
height (cm) Fat  
mass %
lean  
mass %
chO hbgi lbgi
A01 Female 13 6.1 45 7.0 19.03 55.0 170 22.2 77.8 Yes 11.5 1.5
A02 Female 9 5.4 38 8.7 28.08 91.0 180 20.8 79.2 Yes 10.8 1.4
A03 Female 4 6.3 38 8.1 23.14 63.0 165 27.7 72.3 Yes 10.6 1.3
A04 Male 20 4.0 47 7.2 27.40 96.0 190 24.0 76.0 Yes 3.8 2.8
A05 Female 33 8.4 33 7.2 18.80 53.0 168 18.1 81.9 Yes 11.1 1.6
A06 Male 26 8.1 43 7.2 21.90 67.0 175 19.2 80.8 Yes 7.2 4.1
A07 Female 26 3.2 59 7.3 20.60 61.0 172 26.4 73.6 Yes 4.15 5.17
A09 Female 5 4.2 37 8.4 22.60 53.0 153 27.3 72.7 Yes 11.3 1.6
A10 Female 6 3.3 31 7.4 21.10 55.4 162 26.4 73.6 Yes 8.6 6.5
A11 Female 23 2.8 35 7.4 27.10 65.0 155 26.7 73.3 Yes 6.2 3.8
A12 Female 21 3.9 36 6.8 20.40 61.0 173 26.3 73.7 Yes 4.3 4.2
B01 Male 2 5.8 22 7.0 22.78 72.0 178 11.4 88.6 No 10.1 6.5
B02 Male 32 1.2 59 7.5 20.22 53.0 162 17.4 82.6 No 12.2 1.9
B03 Female 28 0.6 40 8.5 25.17 70.0 167 30.5 69.5 No 10.8 1.4
B04 Female 2 4.4 28 6.8 21.09 52.0 157 19.2 80.8 No 11.3 1.6
B05 Male 2 5.6 27 6.5 24.44 74.0 174 26.4 73.6 No 10.8 1.5
B06 Female 2 4.8 25 7.0 18.53 48.0 161 11.5 88.5 No 3.8 2.8
B07 Male 10 4.4 24 7.5 27.04 85.0 188 23.1 76.9 No 12.1 1.8
B08 Female 22 5.1 37 7.0 21.30 61.0 170 19.4 80.6 No 6.2 3.0
B09 Female 2 5.3 43 10 20.70 55.0 163 20.1 79.9 No 10.6 1.3
B10 Male 11 6.0 39 6.5 25.4 75.0 172 26.3 73.7 No 10.3 1.2
B11 Female 6 0.8 42 8.0 22.3 60.0 164 23.3 76.7 No 11.6 1.5
B12 Female 22 2.2 39 6.4 22.00 65.0 172 26.4 73.6 No 7.6 4.5
C01 Male Control 11.2 48
C02 Female Control 9.4 39
C03 Male Control 8.2 51
C04 Male Control 7.9 46
C05 Male Control 9.4 45
C06 Female Control 11.0 28
C07 Male Control 11.4 38
C08 Male Control 11.8 46
C09 Male Control 11.6 48
C10 Female Control 10.9 49
C11 male Control 10.4 37
BMI, body mass index; CHO, carbohydrate counting; HBGI, high blood glucose index; LGBI, low blood glucose index.
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unpaired samples with equal or different variance) for normally 
distributed samples, the analysis of the variance was assessed 
by ANOVA test at the 0.05 level. Once determined the normal-
ity as well as the variance of the samples, the proper test was 
applied to evaluate differences among groups. In particular, we 
used the two-sided Student’s t-test for unpaired samples (either 
with different variance or with equal variance) for normally 
distributed data and the Mann–Whitney U test when samples 
were not normally distributed. In both cases, p <  0.05 was 
considered as significant. The Pearson correlation coefficient 
was calculated to evaluate relationships between cEPC count 
and clinical parameters.
study Design
As depicted in the flow diagram shown in Figure 2, the study 
was divided into two steps. In the first step, two cohorts of 
T1DM patients enrolled in the two (adult and pediatric) diabetic 
centers were analyzed independently. The end point of the first 
step of the study was the evaluation of the number of cEPCs in 
adult and childhood/young patients, compared to controls of 
the same age range. In the second step, the study population 
(a total of 111 patients enrolled in both centers) was divided in 
two groups of similar numerosity, depending on the age (≥ or 
<20 years). The end point of this second step was the analysis 
of the association between the number of cEPCs and disease 
duration and/or patients’ age.
resUlTs
The first objective of our study was to determine the number of 
cEPCs in T1DM patients compared to healthy controls (see the 
flow diagram of the study in Figure 2). Two different patients’ 
cohorts were examined: one relative to adult T1DM patients 
enrolled in the Prato Hospital and one relative to childhood/
young patients, enrolled in the Meyer Pediatric Florence 
Hospital. The clinical characteristics of T1DM patients 
enrolled in the two centers are shown in Tables 1 and 2, along 
with cEPC data. Note that for healthy controls, only gender 
and age data are reported in the tables. The number of cEPCs 
was significantly reduced in adult T1DM patients compared 
Table 2 | Clinical characteristics of childhood/young type 1 diabetes mellitus (T1DM) patients enrolled in the study.
Patient iD gender T1DM duration (years) cePc age hba1c bMi glycemia i/W
PD 001 Male 14 9.2 19 6.5 21.10 67 0.79
PD 002 Male 4 32.6 17 6.6 ND 100 0.68
PD 003 Male 4 16.7 8 6.8 16.40 164 0.65
PD 004 Female 6 9.2 18 8.5 21.60 239 1.16
PD 005 Male 5 2.3 13 9.0 17.30 205 0.74
PD 010 Female 4 8.3 15 7.1 25.70 197 0.45
PD 012 Male 2 0.7 8 7.3 16.40 182 0.84
PD 013 Female 12 11.7 16 8.3 22.90 226 0.82
PD 020 Male 3 0.3 7 9.7 ND 250 ND
PD 021 Male 9 3.0 19 9.8 24.40 90 0.75
PD 022 Male I4 43.3 19 8.6 24.40 271 0.62
PD 025 Female 10 3.6 14 7.8 21.40 142 1.00
PD 032 Male 5 4.5 7 7.5 14.50 119 0.70
PD 033 Female 1 1.8 15 6.3 25.10 126 0.72
PD 035 Male 2 40.3 17 5.7 23.60 186 0.40
PD 037 Female 4 6.8 14 8.2 17.70 212 0.90
PD 040 Male 2 2.7 12 7.6 20.70 107 0.93
PD 041 Male 2 11.9 8 7.5 15.80 114 0.67
PD 042 Female 14 23.4 17 7.5 18.00 289 1.03
PD 044 Female 2 75.0 16 6.5 24.80 108 0.88
PD 045 Male 2 10.2 9 6.5 16.90 122 0.76
PD 046 Male 5 18.3 18 6.7 19.40 179 0.83
PD 047 Male 8 4.5 18 7.2 23.20 164 0.70
PD 048 Female 2 7.6 16 6.0 20.90 117 1.14
PD 049 Female 1 14.0 9 8.0 23.40 208 1.28
PD 050 Female 5 10.6 14 8.0 29.90 102 0.92
PD 051 Female 9 16.4 13 7.4 18.00 304 1.05
PD 054 Male 10 45.8 15 9.5 24.10 220 1.08
PD 055 Female 4 17.5 17 7.7 ND 365 ND
PD 056 Female 5 17.9 10 8.1 15.60 368 0.74
PD 058 Male 4 20.2 15 10.3 ND 270 0.82
PD 063 Female 4 38.3 17 7.5 26.90 164 0.84
PD 064 Male 11 8.4 14 8.1 17.80 83 0.71
PD 065 Female 9 19.0 10 7.5 14.40 174 0.92
PD 066 Male 4 24.2 11 8.0 18.10 205 0.92
PD 067 Male 8 38.6 11 7.3 17.40 102 1.02
PD 068 Female 2 30.4 10 8.7 19.70 203 1.08
PD 069 Female 4 11.3 14 7.2 21.60 270 0.98
PD 070 Female 12 34.4 19 8.7 27.10 163 0.61
PD 071 Male 1 26.8 10 6.8 17.20 146 0.89
PD 073 Male 11 2.4 18 7.3 22.80 183 0.73
PD 074 Male 12 0.3 17 7.0 29.30 106 0.86
PD 075 Male 4 3.3 18 6.1 ND 155 ND
PD 080 Male 5 1.4 16 10.2 19.90 333 1.16
PD 081 Male 8 16.5 14 7.0 30.40 319 0.90
PD 083 Female 9 8.2 13 7.8 18.20 334 1.00
PD 084 Female 2 12.5 17 6.4 22.30 104 0.69
PD 085 Female 1 25.7 14 8.0 23.30 181 0.54
PD 086 Male 6 35.0 10 8.0 15.60 165 0.55
PD 087 Female 1 2.9 6 6.8 15.40 223 0.07
PD 088 Male 10 7.1 13 8.0 17.20 210 1.06
PD 090 Male 8 23.4 15 7.8 19.20 178 0.93
PD 091 Male 1 2.6 16 8.0 21.60 243 0.40
PD 093 Female 2 3.7 10 7.6 17.50 173 0.82
PD 094 Male 4 6.2 16 9.0 23.80 279 0.77
PD 097 Female 2 3.5 16 7.7 26.10 185 0.58
PD 099 Male 13 42.0 19 7.9 ND 54 ND
PD 101 Female 10 4.2 14 7.0 21.50 71 1.06
PD 112 Male 2 5.3 10 7.2 19.10 243 0.74
PD 006 Male Control 18 14
PD 007 Female Control 3.1 15
PD 008 Male Control 4.0 11
PD 017 Female Control 2.3 15
PD 018 Male Control 1.5 7
(Continued )
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Table 3 | Clinical characteristics of adult and childhood/young type 1 diabetes 
mellitus (T1DM) patients enrolled to complete the cohort under study.
center Patient iD T1DM duration 
(years)
cePc age
PO AD 001 14 7.5 49
PO AD 002 12 5.6 50
PO AD 003 14 9.7 40
PO AD 004 12 3.1 47
PO AD 005 18 11.2 35
PO AD 006 11 4.3 43
PO AD 007 10 1.4 32
PO AD 008 13 3.4 38
PO AD 009 20 3.6 38
PO AD 010 18 4.8 32
PO AD 011 22 9.3 56
PO AD 012 28 5.8 39
PO AD 013 30 8.4 42
PO AD 015 32 6.6 42
AOUM PD 011 5 1.2 24
AOUM PD 023 18 4.1 21
AOUM PD 029 6 66.2 22
AOUM PD 031 12 12.5 20
AOUM PD 036 14 10.4 27
AOUM PD 038 13 22.3 23
AOUM PD 052 12 11.1 21
AOUM PD 059 12 15.0 20
AOUM PD 060 12 13.1 22
AOUM PD 092 12 1.2 25
AOUM PD 096 9 10.1 22
AOUM PD 100 11 8.0 21
AOUM PD 109 39 1.5 42
AOUM PD 111 11 0.6 20
FigUre 3 | (a) Circulating endothelial progenitor cell (cEPC) counts 
(absolute cEPC number per 2 × 105 peripheral blood mononuclear cell) in 
adult control subjects (white bar) and adult type 1 diabetes mellitus (T1DM) 
(black bar). Data are reported as mean ± SEM; p < 0.001, Student’s t-test. 
(b) cEPC count in childhood/young control subjects (white bar) and 
age-matched T1DM (black bar). Data are reported as mean ± SEM; 
p < 0.001, Mann–Whitney U test.
Patient iD gender T1DM duration (years) cePc age hba1c bMi glycemia i/W
PD 019 Male Control 3.6 8
PD 057 Male Control 8.7 3
PD 103 Male Control 6.2 7
PD 108 Female Control 0.2 11
PD 113 Male Control 1.7 18
PD 114 Male Control 4.8 7
BMI, body mass index; I/W, insulin/weight.
Table 2 | Continued
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to controls within the same age range (4.43 ± 0.29 n = 23 vs 
10.29 ± 0.68 n = 11; p < 0.001, Student’s t-test) (Figure 3A, raw 
data are in Table 1). On the contrary, childhood/young T1DM 
patients had significantly higher levels of cEPCs (13.90 ± 1.95 
n =  59) compared to control subjects (4.92 ±  0.89 n =  11; 
p < 0.001, Mann–Whitney U test) (Figure 3B, raw data are in 
Table 2). In both cohorts, no statistically significant association 
emerged between the number of cEPCs and available clinical 
parameters, such as gender, percentage of glycated Hb, and 
body mass index (BMI).
We then enrolled 28 T1DM patients from either centers 
(Table  3), so that the study population was: 52 patients in the 
≥20  years group and 59 in the <20  years group. In order to 
evaluate whether the number of cEPCs was anyhow related to 
the patients’ age and/or with the duration of the disease T1DM 
patients from both centers were grouped into two age categories: 
patients younger (<20 years) or older than 20 years (≥20 years). 
In agreement with data shown in Figure 3, the number of cEPCs 
turned out to be significantly higher in T1DM patients younger 
than 20 years with respect to older patients (15.24 ± 1.12 n = 59 vs 
7.27 ± 0.73 n = 52; p = 0.004, Mann–Whitney U test) (Figure 4A).
Once demonstrated that the number of circulating EPCs falls 
with the increasing of age, we evaluated whether the differences 
in cEPCs levels depended only on the age of the patient or also 
on the duration of the disease. To this purpose, we categorized 
T1DM patients into the two groups depending either on the 
age (≥ or <20 years) or on the duration of the disease (shorter 
or longer than 10 years, DD < 10 years or DD ≥ 10 years) and 
divided each group into two subgroups, based on DD and age, 
FigUre 4 | (a) Circulating endothelial progenitor cell (cEPC) counts in type 1 diabetes mellitus patients of different age groups (white bar: age <20 years; black bar: 
age ≥20 years). Data are reported as mean ± SEM; p = 0.004. (b) Histograms summarizing cEPC levels in patients belonging to the different age and disease 
duration groups. Data are reported as mean ± SEM. Left histogram: p = 0.689 and p = 0.418, Mann–Whitney U test. Right histogram: p = 0.153 and p = 0.061, 
Mann–Whitney U test.
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respectively. No differences were found between DD subgroups 
when the patients were categorized by age (Figure 4B, left panel; 
individual means and p values are in figure legend). When the 
patients were categorized on the basis of disease duration, the 
difference in cEPC counts between <20 and ≥20 years patients 
was roughly of the same entity in both DD groups, although 
with a lower p value in the DD ≥  10 years group (Figure 4B, 
right panel; individual means and p values are in figure legend). 
Furthermore, we plotted the individual cEPC count values vs 
either patients’ age or duration (Figure  5). A subset of child-
hood/young patients, aged less than 20 years (and with a disease 
duration less than 10 years) emerged with very high cEPC counts 
(black shaded circles in Figure 5).
DiscUssiOn
In this study, we determined the number of cEPCs in T1DM 
patients without clinical vascular damage, of different ages 
and disease duration. In the first step of the study, cEPCs were 
measured in two separate T1DM patients’ groups, either adults 
or pediatric, in comparison with controls of the same age range. 
In the second step, patients were grouped in two age groups 
(≥ or <20 years) and the number of cEPCs was correlated with 
both the age and the duration of the disease. We provide evidence 
that in T1DM patients without cardiovascular complications, 
the number of cEPCs is significantly correlated with patients’ 
age, whereas does not depend on other clinical parameters, such 
as metabolic control (HbA1c), glycemic variability (MAGE), 
and BMI.
The number of cEPCs in adult T1DM patients turned out 
to be lower compared to both age-matched controls and to 
childhood/young T1DM patients. The latter showed very high 
levels of cEPCs compared to age-matched controls. The lower 
amount of cEPCs found in adult T1DM patients agrees with 
previous studies in both T1DM (20–23) and T2DM patients 
(9, 11–13), while the high number of cEPCs in pediatric T1DM 
patients is in line with what reported by Głowińska-Olszewska 
et al. (25) in T1DM children. Hence, the apparent contradicting 
data in cEPC number reported in T1DM patients in the litera-
ture could be reconciled considering the age of the patients. The 
number of cEPCs apparently changed also in normal subjects. 
In fact, although in a small number of control subjects, we found 
8Arcangeli et al. EPC in Type 1 Diabetes
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FigUre 5 | (a) Scatter plot of the distribution of circulating endothelial 
progenitor cell (cEPC) vs age. Black circles: patients with high endothelial 
progenitor cell (EPC) count. (b) Scatter plot of cEPC vs disease duration. 
Black circles: patients with high EPC count.
an increase in the number of cEPCs from children to adults. 
Most of the data in the literature show a decrease in cEPC 
number in aged subjects (27, 28) and correlate this decrease 
with impairment in endothelial repair and onset of vascular 
damage (29). Our data, along with current literature, suggest the 
necessity to consider an age-related profile of cEPC production 
in physiological conditions. The progressive increase in cEPC 
number until young/adult age, and their progressive decrease in 
the elderly, could also deter mine differences in age-dependent 
cEPC production in pathological conditions.
Another aspect that must be considered when studying the 
number of cEPCs in different conditions is represented by the 
different methodologies used to analyze and quantify them. 
In fact, the phenotypical marker of EPCs is CD133 that is absent 
on mature endothelial cells, and other surface markers are 
CD34+, VEGFR2+, and CD146+ (30). However, to date, there 
are no standardized methods to quantify and identify EPCs and 
the protocols used vary between studies (31). Moreover, most 
studies in both T2DM and T1DM patients were based on the 
deter mination of EPCs based on their growth in vitro (20).
Finally, the different kinds of therapies with insulin (dose 
and number of administration and duration of therapy) could 
also contribute to the different cEPC profiles in T1DM, as shown 
for T2DM patients (32). However, we did not find any association 
between the number of cEPCs and the insulin to weight ratio in 
the pediatric cohort analyzed in the present study.
Besides differences in cEPC number compared to controls, 
the most interesting result of the present study is that child-
hood/young (<20 years) T1DM patients have a higher number 
of cEPCs compared to adult (>20 years) patients. Such higher 
number of cEPCs is maintained also when the disease duration 
is longer than 10  years (Figure  4B, right panel). Moreover, 
a subpopulation of childhood/young T1DM patients, aged 
<20 years, whose disease lasts for less than 10 years are char-
acterized by very high cEPC values. It is tempting to speculate 
whether these young patients with high cEPC levels could be 
protected against endothelial dysfunction. On the contrary, 
when the disease occurs in older age, the low levels of cEPCs 
could mirror a lowering of such protective effect. These still 
preliminary data would support the clinical observation of less 
incidence of late vascular complications in T1DM when the 
onset of the disease is in childhood respect to adult age. We 
wonder whether these effects could be related to a better gly-
cemic control obtained in pediatric patients. In Hörtenhuber’s 
prospective study, an increase in cEPC number after one year 
was reported in association with better glycemic control (24). 
In line with these results, Marfella et  al. (17) showed that 
during percutaneous coronary intervention, an optimal peri-
procedural glycemia control improves myocardial salvage, by 
increasing cEPC number and their capability to differentiate. 
Notably, the same group (16) had shown that a poor glycemic 
control reduces EPC number in T2DM, through a mechanism 
that is mediated by Sirtuin expression (19).
cOnclUsiOn
The present study shows that a relevant association exists bet-
ween the number of cEPCs and the age and duration of the 
disease in T1DM patients. One of the limitations of the present 
study is the relatively small number of patients and short fol-
low up, as well as the lack of data on cEPC functionality, that 
render the data still preliminary. Nevertheless, if appropriately 
circumstantiated in a further study, our results might provide 
an additional explanation to the pathogenesis of complications 
in T1DM as well as to the clinical evidence of less complications 
in T1DM patients when the onset of the disease is in the pedi-
atric age. Moreover, in agreement with current literature, our 
data suggest that maintaining a high number of cEPCs, possibly 
through a good glycemic control, would contribute to contain 
the CVD burden in T1DM.
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